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Clinical and Biochemical Characteristics of Autoantibody 
Systems in Polymyositis and Dermatomyositis 
By Edward J. Fudman and Thomas J. Schnitzer 
P OLYMYOSITIS (PM) and dermatomyosi- tis (DM) are inflammatory muscle diseases 
of unknown etiology. There is strong evidence for 
cellular immune mechanisms of muscle damage 
in these disorders. In recent years, numerous 
autoantibodies have been identified in patients 
with myositis, but their role in producing this 
clinical syndrome is unknown. In this report, we 
summarize the current state of knowledge about 
myositis-related autoantibodies, including char- 
acterization of the antigens, epidemiology, clini- 
cal significance. and the clues these autoanti- 
bodies may provide concerning the etiology and 
pathogenesis of the disease. 
ANTIBODIES TO MUSCLE PROTEINS 
The search for autoantibodies in patients with 
PM started with attempts to detect antibodies 
against muscle fibers and individual muscle pro- 
teins. The initial studies, using indirect immuno- 
fluorescence with muscle as the substrate, found 
no differences among sera of patients with PM, 
other muscle diseases, and normals.’ This may 
have been a consequence of the strong nonspe- 
cific affinity of immunoglobulins for skeletal 
muscle fibers. 
Further investigations of antibodies to specific 
muscle components, particularly human myosin 
and myoglobin, have detected such antibodies in 
sera of patients with PM. Depending on the assay 
used, there is varying specificity for the disease. 
Antibodies to myosin were initially reported to be 
present in almost 50% of sera from patients with 
PM, but were also present in a similar percentage 
of sera from patients with other neuromuscular 
diseases and healthy controls2 Using more 
highly purified myosin, Wada et al have recently 
developed a radioimmunoassay for antibodies to 
myosin and have found such antibodies in 18 of 
20 patients (90%) with PM. A high degree of 
specificity for this assay was claimed as antibod- 
ies were present in only six of 33 patients (18%) 
with other muscle diseases, and then in much 
lower titer. Antibodies to myosin were not 
detected in 43 patients with other neurologic or 
autoimmune diseases3 
Antibodies to myoglobin were reported by 
Nishikai and Homma to be present in seven of 
eleven patients with PM using a double immu- 
nodiffusion assay. None was detected in a total of 
64 patients with rheumatoid arthritis (RA), sys- 
temic lupus erythematosus (SLE), scleroderma, 
and in normals. However, patients with other 
myopathies were not studied as controls.4 In a 
subsequent study, the investigators used a pas- 
sive hemagglutination technique and detected 
antibodies to myoglobin in 71% of patients with 
PM. The antibody was not specific for PM as 
antibodies to myoglobin were also detected in 
patients with myasthenia gravis (3 I%), muscular 
dystrophy (IO%), and in low titer in some 
patients with RA, SLE, and scleroderma.’ 
Antibodies to muscle proteins such as myosin 
and myoglobin are probably nonspecific reac- 
tions to muscle injury and subsequent release of 
these antigens. It is difficult to understand how 
antibodies to such internal muscle proteins could 
play a role in the initiation of muscle damage. 
The assays described above are not generally 
used for the diagnosis or observation of patients 
with PM. 
ANTIBODIES TO NUCLEAR AND 
CYTOPLASMIC ANTIGENS 
In recent years, the focus of study of autoanti- 
bodies in PM has shifted from muscle to subcel- 
lular particles. Some of the autoantibodies are 
detected by immunofluorescence testing and the 
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Table 1. Biochemical Characteristics of Antigens Recognized by Myositis-Related Autoantibodies 




















Properties or Function References 
Protein, binds free ends of dsDNA 6. 7 
Histidyl tRNA synthetase 30,31 
Protein, shares antigenic determinants with 10 
bovine IgG 
Protein, unknown function 11 
Protein, unknown function 12-15 
Ribonucleoprotein containing U 1 RNA 16 
*On human liver substrate; negative on rat liver substrate. 
ton mouse liver substrate. 
$On mouse spleen substrate. 
remainder are identified as precipitin lines in 
double immunodiffusion assays against specified 
tissue extracts (Tables 1 and 2). 
The introduction of human epithelial cells as a 
substrate for antinuclear antibody (ANA) assays 
has greatly enhanced the usefulness of this proce- 
dure to detect autoantibodies in PM. When 
rodent liver or kidney was used as the tissue 
substrate for indirect immunofluorescence, an- 
tinuclear antibodies were detected in about one 
third of patients with PM.2s*26 However, using 
HEp-2 cells (a human-derived cell line) as the 
substrate, 89 of 114 (78%) sera from patients 
with PM were positive. Both nuclear and cyto- 
plasmic staining were observed. The most com- 
mon pattern was fine speckled staining of the 
nucleus (61%), followed by homogeneous cyto- 
plasmic staining (19%), and a nucleolar pattern 
(10%). Other patterns identified were centro- 
mere, small bright speckled, nuclear and cyto- 
plasmic, nucleolar and centromere, and filamen- 
tous cytoplasmic. No single pattern on HEp-2 
cells predominated among the sera that were 
negative on mouse kidney substrate.*’ There are 
no known correlations between the pattern of 
HEp-2 staining and the clinical syndrome. 
Using a complement fixation assay, Reichlin 
and Mattioli in 1976 first detected an antibody to 
calf-thymus extract in the serum of a patient 
with DM.27 Subsequent study of this prototype 
serum, Mi, using agar gel diffusion found at least 
two different precipitating antigens. One, desig- 
nated Mi-1, was a protein with a molecular 
weight (mol wt) of 150,000 daltons that ap- 
peared to bear some antigenic relationship to 
bovine IgG aithough it was not an immunoglobu- 
lin. Antibodies to Mi-1 were detected in two of 19 
patients with DM but in 0 of 39 patients with 
PM, 60 patients with other connective tissue or 
muscle diseases, or 18 healthy controls. Later 
studies of anti-Mi-1 found this antibody to be 
present in about 5% of sera from patients with 
SLE. These sera also contained other precipitat- 
ing antibodies, predominantly Sm or nRNP. 
Anti-Mi-I was not found in sera from patients 
with SLE which did not also contain other pre- 
cipitating antibodies.24 Anti-Mi-1 sera produced 
varying ANA patterns depending on the sub- 
strate used.” 
The second antibody in Mi serum, Mi-2, is the 
complement fixing antibody originally described 
by Reichlin and Mattioli. Of the known autoanti- 
bodies, anti-Mi-2 is the most specific for DM, 
present by ELISA in 11 of 52 patients with DM, 
Table 2. Clinical Characteristics of Myositis-Related Autoantibodies 







50% of PM-scleroderma overlap in Japa- 
nese patients 
30% of PM, <lo% of DM. 50% to 
100% of PM with interstitial lung dis- 
ease 
3% of DM, not detected in PM 
20% of DM. rare in PM 
8% of PM (half have PM-scleroderma 
overlap) 
4% to 15% of PM and DM 
Present in 5% of American patients with 
SLE 
Rarely detected in interstitial lung disease 
without mvositls 
Present in 5% of SLE 
None known 








Common In SLE and overlap svndromes 18.25 
6. 7. 17 
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but in only two of 87 patients with PM. None of 
93 patients with other connective tissue diseases 
or 35 healthy controls had significant titers of 
anti-Mi-2. ELISA proved to be more sensitive 
than immunodiffusion as immunodiffusion de- 
tected anti-Mi-2 only in patients with DM, and 
only in those patients with a strongly positive 
ELISA for Mi-2 antibodies. Studies using par- 
tially purified Mi-2 antigen showed it to be 
protein with major bands of 53,000 and 61,000 
daltons by SDS-polyacrylamide gel electropho- 
resis. Anti-Mi-2 sera yields a homogeneous 
nuclear ANA pattern with either HEp-2 or 
mouse liver substrate.” 
Antibodies to a different cellular antigen were 
identified in 1977 by Wolfe et al, who noted a 
line of precipitation in double immunodiffusion 
between calf thymus nuclear extract and sera of 
patients with myositis.” This antigen-antibody 
system, originally designated PM- 1, was subse- 
quently found to give multiple lines of precipita- 
tion. The predominant antigen has been named 
PM-Scl. Fifty percent to 66% of the patients with 
antibody to PM-Scl have an overlap syndrome of 
scleroderma and myositis; the remainder have 
only PM or DM. The antibody has also been 
rarely found in patients with scleroderma with- 
out myositis.‘3x’4 Antibodies to PM-Scl were 
identified in 8% of 168 myositis patients.25 Long- 
itudinal studies have shown that antibody status 
at time of diagnosis remains constant and does 
not change with disease activity.‘* 
Attempts to characterize the PM-Scl antigen 
have shown it to be primarily nucleolar in loca- 
tion when examined by immunofluorescent tech- 
niquesi3 Further evidence for the nucleolar ori- 
gin of PM-Scl is provided by a study that showed 
nucleolar extracts to be lo- to 50-fold enriched 
for PM-Scl antigen over whole calf thymus 
extract, whereas nucleoli-poor fractions did not 
demonstrate the antigen.” The PM-Scl antigen 
has been shown to be a heat sensitive, trypsin 
sensitive acidic protein and to be DNAse and 
RNAse resistant. It has not been completely 
purified and its function remains unknown.‘2,‘4 
A second autoantibody found in patients with 
PM-scleroderma overlap is anti-Ku. Antibodies 
to Ku were originally described in nine of a series 
of 330 Japanese patients with connective tissue 
disease. Seven had a PM overlap syndrome (six 
PM-PSS, one PM-PSS-SLE), one had PSS, and 
one had SLE. Three of the nine patients also had 
anti-PM-SC1 antibodies6 Anti-Ku has also been 
found in American patients, present in three of 
60 with SLE.” Biochemical studies have shown 
Ku to be a protein that binds specifcally to the 
free ends of double-stranded DNA.’ By indirect 
immunofluorescent technqiues, the antigen has 
been localized to the nucleus but spares the 
nucleolus.6 
At this time, antibodies to Mi-1, Mi-2, PM- 
Scl, and Ku are all laboratory findings without 
any known or hypothesized relationship to the 
etiology or pathogenesis of myositis. The low 
frequency of these autoantibodies in patients 
with PM and DM makes it unlikely that they 
play a significant role in the disease process, 
though their function in any individual patient is 
unknown. Further understanding of the signifi- 
cance of these autoantibodies may not be 
achieved until the target antigens are identified. 
In distinction to these autoantibodies, another 
class that has been extensively investigated are 
those directed against nRNP. Such antibodies 
are usually associated with connective tissue 
diseases other than pure PM, including various 
overlap syndromes with features of SLE, sclero- 
derma, and myositis. However, anti-nRNP has 
also been found in 4% to 15% of sera from 
patients with isolated PM and DM.‘8,25 Antibod- 
ies to nRNP have been shown to react with the 
protein components of ribonucleoproteins con- 
taining Ul RNA.16 Ribonucleoproteins contain- 
ing Ul RNA appear to regulate the posttran- 
scriptional processing of messenger RNA by 
ensuring the precise excision of unneeded seg- 
ments from newly transcribed hetereogeneous 
nuclear RNA.** Anti-RNP antibodies have been 
shown to block this processing activity in cell free 
systems.” However, a relationship between the 
cellular defect and the clinical syndromes in 
which antibodies to nRNP are found has not yet 
been established. A different antibody which 
reacts with ribonucleoproteins of U2 RNA has 
recently been described in one patient with PM- 
scleroderma overlap.*’ The function of this ribo- 
nucleoprotein is currently unknown. 
Antibody to Jo-l was the first autoantibody 
identified with reactivity against a specific en- 
zyme. Using double immunodiffusion with calf 
thymus extract, Nishikai and Reichlin demon- 
strated a strong precipitin line of common speci- 
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ficity in eight of 26 sera (30%) from patients with 
PM and in one of 22 sera (4%) from patients with 
DM. Of 102 patients with other connective tissue 
and muscle diseases, only one, a patient with 
PM-PSS overlap, had antibodies to Jo-l. The 
other ten patients with PM-PSS overlap were 
negative.2’ Subsequent studies have confirmed 
the prevalence of anti-Jo-l in patients with PM 
and DM as 30% and < 1 O%, respectively, and the 
absence of anti-Jo-l in patients with other con- 
nective tissue diseases.‘8x22 In addition to this 
relationship with the clinical presentation, the 
production of antibody to Jo-l may be under 
genetic influence. Arnett et al reported HLA- 
DR3 present in seven of 11 patients with PM who 
were anti-Jo-l positive (64%) but present in only 
eight of 36 patients with PM who were anti-Jo- 1 
negative (22%). No significant difference was 
found in the prevalence of HLA-DRw6 between 
these two groups, but all patients with Jo-l 
antibodies had DR3, DRw6, or both.18 
Examination of the clinical significance of 
antibody to Jo-l has shown a strong association 
between the presence of this antibody and inter- 
stitial lung disease. This association was initially 
recognized by Yoshida et al, who reported find- 
ing antibodies to Jo-l in 11 of 324 Japanese 
patients with connective tissue disease. Ten of 
the patients had PM (including two with overlap 
syndromes) and one had DM. All 11 patients had 
interstitial lung disease by chest x-ray. In con- 
trast, interstitial lung disease was present in only 
22% of the patients with PM or DM who had no 
detectable antibody to Jo-l. There was no rela- 
tionship between the titer of antibody to Jo- 1 and 
the severity of the interstitial lung disease, 
assessed either by chest x-ray or diffusion capac- 
ity. The presence of interstitial lung disease was 
the only difference detected between patients 
positive and those negative for antibody to Jo-l. 
There were no significant differences between 
these groups in age at diagnosis, sex, creatine 
kinase elevation, or response to corticosteroids.” 
In other studies, Bernstein et al reported finding 
20 English patients with antibodies to Jo-l after 
screening 1,000 sera. Thirteen of the patients 
had PM with interstitial lung disease. In two of 
the patients with PM, antibody to Jo-l was 
present when the patients had lung disease alone, 
before myositis was diagnosed. Of the 20 
patients, two had interstitial lung disease and 
sclerodactyly in the absence of myositis.23 This 
association between antibody to Jo-l and PM 
with interstitial lung disease had also been con- 
firmed in American patients.29 After the associa- 
tion was identified, it was reported that the 
American patient who provided the prototype 
serum did have PM with interstitial lung dis- 
ease.* 
Attempts to localize the Jo-l antigen within 
the cell have failed to produce consistent results. 
About 33% of sera containing antibody to Jo-l 
are ANA-positive using mouse kidney substrate, 
a prevalence similar to that found in sera from 
patients with PM lacking antibody to Jo- 1. How- 
ever, using HEp-2 cells as substrate, up to 66% of 
the sera with antibody to Jo-l could be shown to 
have ANA activity. Staining was predominantly 
nuclear, although cytoplasmic and nucleolar pat- 
terns were also seen.25 The reason for the nuclear 
localization is unknown as Jo- 1 is believed to be a 
cytoplasmic enzyme. However, a preliminary 
investigation showed that antibody partially 
purified from two sera originally demonstrating 
nuclear fluorescence did give cytoplasmic flue- 
rescence. The suggestion has been made that 
there may be a factor in whole serum that 
interferes with detection of Jo- 1 antigen by indi- 
rect immunofluoresence.’ 
Extensive biochemical characterization of the 
Jo-l antigen has been accomplished, yielding 
interesting and provocative results. Initial inves- 
tigations identified both protein and transfer 
RNA (tRNA) in the immunoprecipitate formed 
between HeLa cell extracts and serum contain- 
ing antibody to Jo-l. Further studies by Mat- 
thews and Bernstein showed that sera containing 
antibody to Jo-l could block the charging of 
histidine to its tRNA. They therefore postulated 
that Jo-l could be a histidyl-tRNA synthetase.30 
This was confirmed by Yang et al, who purified 
histidyl-tRNA synthetase from rat liver and 
showed it to be identical to the Jo- I antigen.3’ 
Since these studies, other tRNA-related 
autoantibodies have been detected in a small 
number of sera from patients with myositis. An 
autoantibody originally called PL-7 and directed 
against threonyl-tRNA32 was found in sera of 
five patients, four of whom had myositis. A 
similar autoantibody, which precipitated a ribo- 
nucleoprotein complex containing threonyl- 
tRNA and an unknown small RNA molecule, 
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was reported in the sera of one patient with PM,33 
and yet a third antibody, directed against both 
alanyl-tRNA synthetase and deproteinized 
tRNA, has been recently described.34 
As with the previously described autoanti- 
bodies, no evidence directly linking these anti- 
bodies to the pathogenesis of muscle disease has 
been presented. Rather, the antibodies may serve 
as a clue to the etiology of PM. Identification of 
Jo-l and other tRNA-synthetase related anti- 
bodies has furthered speculation that PM is 
initiated by a viral infection. This association is 
based on two related facts. First, some of the 
RNA viruses of the enterovirus group have been 
shown to mimic small tRNAs in their ability to 
be charged with specific amino acids.35v36 Second- 
ly, at least some cases of PM have been thought 
to have a viral etiology, and enteroviruses have 
been implicated in a range of muscle disorders. 
Coxsackieviruses, in particular, are known to 
produce both acute (Bornholm disease) as well as 
chronic (myocarditis) muscle disease. 
On the basis of these data, Matthews and 
Bernstein have hypothesized that antibodies to 
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tRNA synthetase seen in patients with PM may 
result from the binding of the charging enzyme 
complex to viral RNA, rendering the host 
enzyme immunogenic. 3o Thus, once a chronic 
inflammatory muscle disease has been estab- 
lished, the antibodies that have developed to the 
patient’s own charging enzymes may be the only 
evidence remaining of a prior viral infection. 
It is not known if these or any of the other 
autoantibodies found in patients with PM play a 
role in perpetuating the muscle inflammation or 
are merely epiphenomena. The variety of autoan- 
tibodies found in PM and DM serve to emphasize 
the heterogeneity of these syndromes. In the case 
of antibody to Jo- 1, it is likely that its presence 
reflects the occurrence of a prior viral infection 
that may have acted to initiate the immuno- 
pathologic process observed in patients with PM, 
and thus may serve as a way of defining a 
particular clinical subset. Study of this more 
homogeneous group of patients may then lead to 
further understanding of both the etiology and 
pathogenesis of the inflammatory muscle dis- 
eases. 
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